Our results led us to hypothesize that the NF-κB signalling pathway was an important contributor in the development of OXA resistance in this model12 and that a reasonable strategy for CRC cancer treatment may be the combination of OXA-based chemotherapy with compounds active against NF-κB. The gene discussed is NFKB1; the disease is cancer.